n.赫尼根
网络 赫尼根
"The downside of the harms outweighs the one-day reduction in symptomatic benefits," Heneghan said.
“造成伤害的负面作用大于减轻一天症状的正面作用。”Heneghan说道。
Heneghan said the current policy of giving Tamiflu for mild illness was an "inappropriate strategy".
Heneghan认为,当前对于温和流感使用达菲进行医治的策略是“不妥当的”。
"The problem is a resistance issue," said Heneghan. "Going forward we have a treatment which is ineffective because we´ve given it to everybody."
“问题在于抗药性,”Heneghan说道,“这样继续下去,我们的治疗方法将不再起作用,因为我们给所有人都使用这种处方。”